von Schilling Christoph
III. Medizinische Klinik der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 München, Germany.
Semin Cancer Biol. 2003 Jun;13(3):211-22. doi: 10.1016/s1044-579x(03)00018-x.
The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic lymphocytic leukaemia cells, and on all mature reactive B-cells. This review will summarise the modes of action of various reagents targeting CD20. Treatment results following their use in single and combination therapy for B-cell disorders are reviewed.
B 细胞表面抗原 CD20 目前是成熟 B 细胞恶性肿瘤以及一系列反应性 B 细胞相关疾病（包括病毒相关的淋巴细胞增殖或自身免疫性疾病）近选择性治疗的主要靶点。除慢性淋巴细胞白血病细胞外，CD20 在大多数成熟 B 细胞肿瘤以及所有成熟反应性 B 细胞上均呈强而均匀的表达。本综述将总结靶向 CD20 的各种试剂的作用模式。对其在 B 细胞疾病单药治疗和联合治疗中的治疗结果进行了综述。
